scholarly journals Cutaneous Sarcoidosis of a 53-Year-Old Female: A Case Report

Cureus ◽  
2021 ◽  
Author(s):  
Ali Alghamdi ◽  
Nadia Mazraani ◽  
Salman A Thabet ◽  
Basel M Alghamdi ◽  
Maha Hanawi ◽  
...  
Keyword(s):  
Case Report ◽  
Cutaneous Sarcoidosis

scholarly journals CUTANEOUS SARCOIDOSIS IN PATIENT WITH RHEUMATOID ARTHRITIS DURING TREATMENT WITH ADALIMUMAB: CASE REPORT

2019 ◽  
Author(s):  
RUY SAMPAIO SIQUEIRA NETO ◽  
LEILA PATRÍCIA FONSECA OLIVEIRA ◽  
ANDRÉ GOIS ROCHA ◽  
CRISTIANO NOGUEIRA MARQUES ◽  
PRISCILLA MARIANA FREITAS AGUIAR FEITOSA ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Case Report ◽  
Cutaneous Sarcoidosis

The effectiveness of etanercept in treating cutaneous sarcoidosis: a case report

2004 ◽  
Vol 50 (3) ◽  
pp. P55
Author(s):  
Christiane Querfeld ◽  
Peter Bachmann ◽  
Joan Guitart
Keyword(s):  
Case Report ◽  
Cutaneous Sarcoidosis

scholarly journals New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review

2019 ◽  
Vol 11 ◽  
pp. 1759720X1984179 ◽  
Author(s):  
Rosaria Del Giorno ◽  
Alfonso Iodice ◽  
Cristina Mangas ◽  
Luca Gabutti
Keyword(s):  
Case Report ◽  
Clinical Response ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Case Reports ◽  
Skin Lesions ◽  
Cutaneous Sarcoidosis ◽  
Cutaneous Lesions ◽  
Topical Corticosteroids ◽  
New Onset

Background: New-onset sarcoidosis has been previously described in three case reports in patients affected by rheumatoid arthritis treated with tocilizumab (TCZ). The existence of a cause–effect mechanism between the biological treatment and the onset of the illness is still being debated. Patient concerns: A 74-year-old woman was diagnosed with giant cell arteritis (GCA). The first-line treatment with glucocorticoids; and the second-line with methotrexate and low-dose glucocorticoids were stopped due to multiple pathological vertebral fractures and insufficient biological and clinical response. The cytotoxic agent, cyclophosphamide, was then introduced and in turn stopped, because of gastrointestinal side effects. Thereafter a treatment with TCZ was begun. The patient experienced good clinical response; however, 8 months later she developed painful hyper-pigmented reddish cutaneous micronodular lesions localized to the abdomen and thorax. A cutaneous biopsy was performed, and histological analysis showed noncaseating epithelioid granulomas in the hypodermis. The diagnosis of cutaneous sarcoidosis was made. Interventions: Topical corticosteroids were administered and, as requested by the patient, TCZ was discontinued with slow but complete resolution of the skin lesions. After TCZ discontinuation however, the GCA flared and the patient’s symptoms and biological abnormalities reappeared. Thus, after a 6-month suspension, TCZ was re-administered. At 2 months later the skin lesions compatible with cutaneous sarcoidosis reappeared. Topical corticosteroids were once again prescribed and as suggested by the patient the TCZ posology was reduced. The patient’s symptoms disappeared, and the cutaneous lesions resolved. Lessons: The time elapsed from TCZ treatment start and the onset of cutaneous sarcoidosis, as well as its recurrence after TCZ suspension and rechallenge supported the diagnosis of a drug-induced reaction. To the best of our knowledge, this case report represents the first instance of cutaneous sarcoidosis most likely induced by TCZ in patients affected by GCA. In addition, our case emphasizes that although TCZ in monotherapy confirms to be an effective treatment for GCA, further immunological disorders could be unmasked, and the discussed side effect of the drug could be dose-dependent.

Necrobiosis Lipoidica Mimicking Cutaneous Sarcoidosis Finally Treated With an Intralesional Injection of Corticosteroid: A Case Report

2019 ◽  
Vol 19 (1) ◽  
pp. 92-94
Author(s):  
Mohamad Goldust ◽  
Ghasem Rahmatpour Rokni ◽  
Jeffrey Weinberg ◽  
Leon Kircik ◽  
Martine Bagot ◽  
...  
Keyword(s):  
Case Report ◽  
Intralesional Injection ◽  
Necrobiosis Lipoidica ◽  
Cutaneous Sarcoidosis

scholarly journals Cutaneous sarcoidosis masquerading as chronic cutaneous lupus erythematosus - case report

2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Marjon Vatanchi ◽  
Kaivon Sobhani ◽  
Valerie T. Fisher ◽  
Jeffrey J. Meffert
Keyword(s):  
Case Report ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Cutaneous Sarcoidosis ◽  
Cutaneous Lupus

Cutaneous Sarcoidosis Successfully Treated with Alefacept

2006 ◽  
Vol 10 (6) ◽  
pp. 300-303 ◽  
Author(s):  
Jorge Garcia-Zuazaga ◽  
Neil J. Korman
Keyword(s):  
T Cells ◽  
Case Report ◽  
Lymphocyte Activation ◽  
Multiple Organ ◽  
Unknown Etiology ◽  
Cutaneous Sarcoidosis ◽  
Lupus Pernio ◽  
Organ Systems ◽  
Antigen Presenting ◽  
Cell Inhibition

Background: Sarcoidosis is a systemic granulomatous disease of unknown etiology that affects multiple organ systems, including the pulmonary, lymphatic, skeletal, and integumentary systems. Improved understanding of the intrinsic immunology and molecular biology in sarcoidosis can be applied to the treatment of this disease. Alefacept is a human fusion protein consisting of the extracellular domain of leukocyte function-associated antigen 3 fused with the Fc portion of human immunoglobulin G1. It works by blocking the interaction between antigen-presenting cells and T cells to inhibit activation and by inducing apoptosis of CD4+ T cells. In this case report, we describe a 46-year-old patient with recalcitrant lupus pernio who was successfully treated with alefacept. Objective: To determine whether T-cell inhibition, specifically the use of alefacept, may be used to treat a patient with recalcitrant cutaneous sarcoidosis. Methods: Case report. Results: There was a modest clinical improvement after 8 weeks of intramuscular injections of alefacept. Conclusion: This case report provides further evidence of successful treatment of sarcoidosis with biologic agents directed against T-lymphocyte activation.

Sign in / Sign up

Export Citation Format

Share Document